Cargando…

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

INTRODUCTION: We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration. CASE PRESENTATION: A 58‐year‐old patient with heavily pretreated metastatic castration‐resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Motohiro, Komai, Yoshinobu, Yuasa, Takeshi, Numao, Noboru, Yamamoto, Shinya, Fukui, Iwao, Yonese, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292086/ https://www.ncbi.nlm.nih.gov/pubmed/32743472 http://dx.doi.org/10.1002/iju5.12144

Ejemplares similares

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
por: Fujiwara, Motohiro, et al.
Publicado: (2021)

The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma
por: Yoshitomi, Kasumi Kaneko, et al.
Publicado: (2021)

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy
por: Yasuoka, Shotaro, et al.
Publicado: (2021)

External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer
por: Fukagawa, Eri, et al.
Publicado: (2021)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
por: Sano, Masayuki, et al.
Publicado: (2016)

De novo large‐cell neuroendocrine carcinoma of the prostate: A case report and literature review
por: Fukagawa, Eri, et al.
Publicado: (2022)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
por: Uehara, Sho, et al.
Publicado: (2015)

Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis
por: Sano, Yuta, et al.
Publicado: (2020)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome
por: Urasaki, Tetsuya, et al.
Publicado: (2021)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Recent advances in medical therapy for metastatic urothelial cancer
por: Yuasa, Takeshi, et al.
Publicado: (2018)

Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
por: Shimizu, Kosuke, et al.
Publicado: (2022)

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
por: Barata, Pedro, et al.
Publicado: (2020)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma
por: Inamura, Kentaro, et al.
Publicado: (2019)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
por: Senda, Masaya, et al.
Publicado: (2023)

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer
por: Yamamoto, Shinya, et al.
Publicado: (2013)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)
por: Yoshida, Soichiro, et al.
Publicado: (2023)

A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
por: Guedikian, Annie A., et al.
Publicado: (2021)

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
por: Ikeda, Yuki, et al.
Publicado: (2021)

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer
por: Kai, Yugo, et al.
Publicado: (2021)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
por: Domingo-Musibay, Evidio, et al.
Publicado: (2018)

Metastatic Malignant Perivascular Epithelioid Cell Tumors With Microsatellite Instability Within Lynch Syndrome Successfully Treated With Anti-PD1 Pembrolizumab
por: Djerroudi, Lounes, et al.
Publicado: (2023)

Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab
por: Naganuma, Atsushi, et al.
Publicado: (2020)

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery
por: Woods, Alexander D., et al.
Publicado: (2022)

Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2016)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d1tfglsg3bl3v9ek34r7fl2c37